Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. grew its stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 13.9% during the third quarter, Holdings Channel reports. The firm owned 677,162 shares of the company’s stock after purchasing an additional 82,864 shares during the period. JPMorgan Chase & Co.’s holdings in Lineage Cell Therapeutics were worth $613,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Rhumbline Advisers increased its position in Lineage Cell Therapeutics by 15.1% in the 2nd quarter. Rhumbline Advisers now owns 132,491 shares of the company’s stock valued at $132,000 after acquiring an additional 17,411 shares during the period. Defender Capital LLC. grew its holdings in Lineage Cell Therapeutics by 0.6% in the third quarter. Defender Capital LLC. now owns 5,002,198 shares of the company’s stock valued at $4,528,000 after purchasing an additional 29,223 shares during the last quarter. MAI Capital Management increased its position in shares of Lineage Cell Therapeutics by 2.2% in the third quarter. MAI Capital Management now owns 1,674,679 shares of the company’s stock valued at $1,516,000 after buying an additional 35,907 shares in the last quarter. State Street Corp increased its holdings in Lineage Cell Therapeutics by 1.8% during the 3rd quarter. State Street Corp now owns 2,608,352 shares of the company’s stock valued at $2,361,000 after acquiring an additional 45,483 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in Lineage Cell Therapeutics during the third quarter worth about $46,000. Hedge funds and other institutional investors own 62.47% of the company’s stock.

Analysts Set New Price Targets

LCTX has been the subject of a number of recent research reports. D. Boral Capital reiterated a “buy” rating and set a $2.00 price objective on shares of Lineage Cell Therapeutics in a research report on Friday, January 3rd. HC Wainwright raised their price target on Lineage Cell Therapeutics from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. Finally, Maxim Group cut their target price on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $4.80.

Lineage Cell Therapeutics Trading Down 3.3 %

Lineage Cell Therapeutics stock opened at $0.62 on Tuesday. The company has a market cap of $135.56 million, a P/E ratio of -5.13 and a beta of 1.18. Lineage Cell Therapeutics, Inc. has a one year low of $0.48 and a one year high of $1.61.

Lineage Cell Therapeutics Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.